Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
We investigated (1) whether transverse aortic constriction (TAC)-induced pressure overload caused Ca2+ leak through cardiac ryanodine receptor (RyR2), and (2) whether chronic administration of dantrolene, a RyR2 stabilizer, inhibited the cardiomyocyte hypertyrophy and dysfunction by stopping the Ca2+leak.The aberrant Ca2+ leak through RyR2 was observed even in the compensated pressure-overloaded heart. Dantrolene restores the cardiomyocyte dysfunction and inhibits the cardiomyocyte hypertrophy by inhibiting the aberrant Ca2+ leak through RyR2. Targeting RyR2 treatment by dantrolene may be a novel strategy for pressure-overloaded hypertrophy.
|